ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
Antonio Jose Tiburcio Alves Junior, Gustavo Alejandro Gutierrez Espinoza, Luciane Hiane Oliveira, Sergio Oliva Banci, Joaquim Simoes Neto, Odorino Hideyoshi Kagohara, Jose Alfredo Reis Junior, Jose Alfredo Reis Neto
Introduction: The mortality rate in cancer of the lower rectum is related to the incidence of local recurrence, in the first 5 years. For stage I tumors, local excision has being increasingly used, but recent studies showed a higher incidence rate of local re…
Marisol Rodríguez, Fernando Mejia, Mariana Lecourtois, Victoria Domínguez, Julieta Castillo
Introduction: Every year, more than 10 million women are diagnosed worldwide with breast cancer. Breast cancer remains the leading cause of death from malignancy in women. In Mexico about 12 Mexican women die every day from this disease. Glutathione S-transfe…
Mohamed Lotayef, Azza Taher, Hanna Attia, Azza Nasr, Hisham El Hossieny, Mohammed Mahmoud, Noha Essam
Purpose: This work was to study the clinic-epidemiological characteristics of patients with locally advanced NCSLC and to analyze their prognostic factors and also the results of different treatment modalities for local control and their effect on overall sur…
Natalie Desiree Klass, Richard P. Baum, Michael Schmuecking, Norbert Presselt, Klaus-Michael Mueller, Thomas G. Wendt, Reiner Bonnet
Introduction: CT alone cannot provide sufficient information referring to response after neoadjuvant therapy in a timely manner. To evaluate the role of 18 F-FDG-PET after neoadjuvant chemoradiation as a valid, non-invasive predictor for early therapy respons…
Kalyan J. Gangavarapu, Alok Bhushan, James C. K. Lai, Christopher K. Daniels
Several factors could contribute to proliferation of multiple myeloma (MM) cells independent of interleukin-6 (IL6) in the later stages of the disease. Our previous studies established a dexamethasone-resistant 7TD1 cell line (7TD1-Dxm) and have shown that on…
Pavla Brachova, Samuel R. Mueting, Eric J. Devor, Kimberly K. Leslie
Mutations in the tumor suppressor TP 53 occur in almost all advanced ovarian cancers and in many advanced serous endometrial cancers. Mutations in TP 53 can alter the function of the p53 protein, and some mutations result in a mutated protein with oncogenic a…
Hend Ahmed El-Hadaad, Hanan Ahmed Wahba, Ibrahim Awad
Purpose: To assess the response rate, duration of response and prognostic factors affecting response after low-dose involved-field radiotherapy in patients with relapsed low-grade B-cell non-Hodgkin lymphoma. Patients and Methods: Forty-four patients were inc…
Thais Montezuma, Elaine Caldeira de Oliveira Guirro, Maíta Mara de Oliveira Lima Leite Vaz, Sebastián Vernal
Background: Women undergoing mastectomy may have postural asymmetries due to mutilation, culminating in changes in postural balance. Aim: This study aimed to evaluate the influence of the mastectomy in the postural control of women undergoing surgical treatme…
Georgios Androutsopoulos, Georgios Michail, Georgios Adonakis, Georgios Decavalas
The Epidermal Growth Factor system is present in human organs and plays an important role in cell proliferation, differentiation and apoptosis during embryogenesis and postnatal development. It has four receptors (EGFR, ErbB-2, ErbB-3 and ErbB-4) and numerous…
P. M. Gaye, A. A. Kassé, D. Diouf, M. M. Dieng, A. Dem
In Senegal, few studies have been devoted to non-Hodgkin’s lymphoma. We conducted a retrospective descriptive study of 73 cases treated at the Institut J. Curie Hospital Aristide Le Dantec for non-Hodgkin’s lymphomas from 2001 to 2007. The main objective was…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).